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HASIL RAWATAN KELOID DENGAN PELBAGAI MODALITI DI KALANGAN 
PUSAT-PUSAT RAWATAN  
Abstrak 
Pengenalan:Parut keloid adalahsejenisketumbuhanfibroblas dermalyang 
tidakmerbahaya. Iamelibatkanpemendapankomponen – 
komponenmatriksekstraselularsepertikolagen, fibronectin, elastin, 
proteoglycans dan “growth factor”seperti TGF-β secaraberlebihan. 
Kondisiiniadalahamatsukardirawat, 
walaupundenganpenggunaanpelbagaistrategirawatan yang 
kerapdiperhatikandalamamalanklinikalharian. Oleh itu, 
pelbagaimodalitirawatandisyorkandigunabersamauntukpengawalan optimum 
penyakitini. Kajian inibertujuanmenilaihasilrawatanparut keloid dengansuntikan 
triamcinolone acetonide (TAC) dan urutanparutdi hospital-hospital tempatan, 
bagimenentukanrawatan optima untukparut keloid bagipopulasitempatan. 
 
Kaedah:Iniadalahkajianprospektif yang dijalankan di Unit SainsRekonstruktif, 
Hospital UniversitiSains Malaysia (Hospital USM) dan 
JabatanPembedahanPlastik danRekonstruktif, Hospital Kuala Lumpur (HKL). 
Kajian inimelibatkanpengumpulanskor – skor POSAS daripesakit – pesakit 
keloid di sepanjangrawatandengansuntikanTAC danurutanparut. Skor – skor 





Keputusan Kajian:Hasil rawatandianalisadenganmenggunakan ‘one-way 
repeated measures ANOVA’. Kesemuakomponen-komponenpesakit dan 
pemerhatiPOSAS menunjukkanpenambahbaikanparut keloid 
dariawalhinggakepenghujungrawatan. Komponenpesakit: kesakitan (39.04%), 
kegatalan (36.45%), ketebalan (30.40%), ketegangan (23.62%), ketidak-
sekataan (20.50%), warna (10.18%) (NS), secarakeseluruhan (20.50%) and 
total (26.74%). Komponenpemerhati: vaskulariti (44.19%), kelegaan (36.94%), 
ketebalan (34.67%), keluasanpermukaan (34.55%), kelembutan (34.22%), 
pigmentasi (16.58), secarakeseluruhan (34.63%) and total (33.93%).Skor-
skorpesakitsecarakeseluruhan dan totalmenunjukkanpenambahbaikan yang 
ketaradenganperbezaan mean 1.43 (p=0.016) dan 9.50 (p<0.001)masing-
masing, dan skor-skorpemerhatisecarakeseluruhan dan total 
menunjukkanpenambahbaikan yang ketaradenganperbezaan mean 2.99 
(p<0.001) dan 9.30 (p<0.001)masing-masing. 
 






factor yang lebihpenting, dan bukanketidakkonsistenanwarna. 
Secarakeseluruhan, suntikan TAC dan urutanparutadalah kos efektif dan 




Kata Kunci:Keloid; Pelbagaimodaliti; Triamcinolone acetonide; TAC; 
Urutanparut; POSAS  
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KELOID: MULTICENTRE STUDY ON THE OUTCOME OF MULTIMODALITY 
MANAGEMENT  
Abstract 
Introduction: Keloids are benign hyperproliferative growths of dermal 
fibroblasts characterized by the excessive deposition of extracellular matrix 
components, especially collagen, fibronectin, elastin, proteoglycans, and growth 
factors such as TGF-β. They remain difficult to improve despite a plethora of 
advocated treatment strategies frequently observed in daily clinical routine. 
Hence, multimodality treatment is often recommended for optimum control of 
the disease. This study aims to assess the outcome of intralesional 
triamcinolone acetonide (TAC) injections with concurrent scar massage in 
management of keloid scarring in our setting, in order to optimise its 
management in the local population. 
 
Methods:This is a prospective observational study conducted in the 
Reconstructive Sciences Unit, Hospital UniversitiSains Malaysia (Hospital USM) 
and the Department of Plastic & Reconstructive Surgery, Hospital Kuala 
Lumpur (HKL). This study involves the collection of POSAS scores from 
patients with keloid scars while they undergo treatment with intralesional TAC 
injections with concurrent scar massage.The POSAS scores is used to analyse 




Results:The one-way repeated measures ANOVA was applied to assess the 
outcome of treatment. All patient and observer components of the POSAS 
showed improvements in keloid scars between the initial and conclusion visit. 
Patient components: pain (39.04%), itch (36.45%), thickness (30.40%), stiffness 
(23.62%), irregularity (20.50%), colour (10.18%) (NS), overall (20.50%) and 
total (26.74%). Observer components: vascularity (44.19%), relief (36.94%), 
thickness (34.67%), surface area (34.55%), pliability (34.22%), pigmentation 
(16.58), overall (34.63%) and total (33.93%). The overall and total patient 
scores showed significant improvements by mean differences of 1.43 (p=0.016) 
and 9.50(p<0.001)respectively, while the overall and total observer scores 
showed significant improvements by mean differences of 2.00 (p<0.001) and 
9.30 (p<0.001) respectively. 
 
Conclusion:The treatment of keloid scars with intralesional TAC injections and 
concurrent scar massage is found to be effective in the Malaysian population. 
These improvements were demonstrated through the use of the POSAS. 
Cosmetic concerns appear to predominate the help-seeking behaviour of 
patients, with a persistence of these characteristics at the end of the study. 
Clinical assessment, however reveal contour deformity to be tenacious, rather 
than colour inconsistency. Nevertheless, in totality, the combination of 
intralesional TAC with scar massage is a cost effective yet clinically potent 
regime effective in improving keloid scars in the local setting. 









1.1.1 Definition of Keloids 
In 1806, French dermatologist, Jean Louis Alibert was the first to coin the 
term keloid from the Greek word “cheloides”, of which carries the 
meaning of “claw” to describe the leg-like projections of scars into the 
surrounding normal skin.  
Keloids are benign hyperproliferative growths of dermal fibroblasts 
characterized by the excessive deposition of extracellular matrix 
components, especially collagen, fibronectin, elastin, proteoglycans, and 
growth factors such as TGF-β (1). It is a variant of abnormal scarring 
resulting from abnormal wound healing after dermal injury, in which the 
healing process results in aberrant scar tissue formation.  
While keloidshave some tumor-like properties, theyare actually 
inflammatory conditions that drive the excessive proliferation ofdermal 
fibroblasts and the aberrant accumulation of dermal matrix(2). 
 
1.1.2 Aetiology 
Its aetiology is unknown,  but studies suggest that it results from the 
interaction of genetic and immunological factors with environmental 
triggers(3).The risk of developing keloids is particularly high if the injury is 
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deep enough to damage the reticular layer of the dermis and if various 
genetic, systemic, and/or local risk factors that prolong the inflammatory 
stage of wound healing are present(2). 
 
1.1.2(a) Genetic and Immunology 
The genetic basis of keloid pathogenesis has been studied extensively 
throughout the past decades. The observation that keloids occur more 
frequently in darker skinned individuals provided an initial suggestion of 
genetic predisposition towards its development(4).Halim AS et al. 
presented a comprehensive summary on the genetic basis of keloid 
scarring (3). 
 
Evidence from Ethnic Groups 
The distribution of keloid scarring in relation to ethnicity is well observed 
and documented. It was found to be the fifth most common skin disease 
inadult black patients in the United Kingdom, after acne, acne keloidalis 
nuchae/scalp folliculitis, eczema and psoriasis(5). It was also found to be 
the most common in Chinese in comparison to other races in multiracial 
Malaysia(6). 
 
Evidence from Families and Twins 
Both autosomal dominant(7) and recessive(8) modes of inheritance have 
been suggested in the literature. In 1969, Marnerosand 
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coworkersexamined the pedigree of 14 families with familial keloids, over 
up to 4 generations, and concluded that the pattern of inheritance 
observed is consistent with an autosomal dominant mode with 
incomplete clinical penetrance and variable expression(7). Marneros et al. 
later extended the study with gene scans, and provided the first evidence 
for keloid susceptibility loci on chromosomes 2 (2q23) and 7 (7p11)(9). In 
addition, the high frequency of identicaltwins both developing keloids 
also strongly supports a role ofgenetics in keloid etiology(8). 
 
Evidence from Syndromes with Keloid Scarring 
Individuals with certain rare syndromes have been found to have higher 
propensity to develop keloids. These include Rubinstein–Taybi 
syndrome, Goeminne syndrome, Ehler–Danlos syndrome, Dubois 
syndrome, Pachydermoperiostosis, Progeria and Osteopoikilosis(10).In 
contrary, the absence of reported cases of keloids in certain subsets of 
individuals, as in individuals with albinism, reinforces the genetic 














Endocrine dysfunction is associated with the keloid disease. Various 
hormones have been described, in particular the sex hormones 
oestrogen and androgens.Other hormones postulated to be associated 
with keloids include the melanocyte stimulating hormone (MSH) and 
growth hormone (thyrotropin). 
The onset or worsening of keloid scars during adolescence and 
pregnancy, as well as its regression in the post-menopausal period 
provided early suggestions that alterations in hormonal status may be 
associated with keloids. Cases discussing on the increased keloidal 
tendencies accompanying pregnancy has been reported in the literature 
(11, 12). As oestrogen is known to exert its influence on all phases of 
wound healing (13), it may have a role in keloid scarring.  
States of hyperpituitarism may explain the mechanism whereby 
aberrations in the hypothalamic-pituitary-glandular axis results in 
increased propensity to develop keloids. MSH metabolism abnormalities, 
hyperthyroidism, acromegaly or even pregnancy has been linked to 





In their publication in 2014, Huang and Ogawa explored the link between 
hypertension and the development of pathological scars, and found that 
hypertension is associated with the development of severe keloids(14). 
The development of keloids was proposed to be the result of excessive 
wound healing characterized by a prolonged and stronger inflammatory 
phase due to inappropriately released cytokines, namely TGF-β and 





Mechanical forces exerted on cutaneous wounds contribute to the 
generation of keloids (16). Clinically, this is evidenced by the site-specific 
incidence and shape of keloids in accordance to the region-specific 
distribution of skin tension(16). Not only does this explain the usual site 
distribution of keloids (shoulder, arm and anterior chest), but also its 
corresponding shapes (butterfly, dumbbell and crab claw). 
 
Trauma, Infection, Foreign Body 
Recurrent local trauma, infection and presence of foreign bodies are also 
known to trigger inflammation and downstream fibroproliferative events 
(17). This may explain the occurrence of keloids at the earlobes: 
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mechanical forces from heavy earrings, repeated injury from attaching/ 




1.1.3(a)Normal Wound Healing 
The American Wound Society defines a wound as a disruption in 
anatomical structure and function. Therefore, wound healing is the 
response mounted by an organism in order to limit the disruption, restore 
the integrity and stabilize the physiology of the entire organism. It is a 
highly coordinated process consisting of overlapping phases which 
proceeds in a timely manner(18) (Figure 1.1). Howes, Sooy and Hawey 
(1929) temporally grouped wound healing into 3 distinct phases; 
inflammation, proliferation and remodelling. Scarring is the final outcome 
of cutaneous wound healing. 
 
Figure 1.1: The temporal patterns of repair phase, cellular influx, 




Immediately following wounding, TXs, PGs and serotonin released by 
damaged cells cause transient vasoconstriction lasting 5 – 10 minutes. 
The exposure of collagen and subendothelium to the blood stream 
triggers platelet aggregation and activation of the coagulation and 
complement cascades. This results in the formation of a platelet 
plug.Subsequent platelet degranulation leads to the formation of a stable 
clot, which consists of a provisional fibrin matrix with embedded platelets. 
Platelet degranulation leads to the release of potent cytokines such as 
PDGF, vWF, IGF1, EGF andTGF-β. These factors serve as chemotactic 
agents which recruits neutrophils, macrophages, epithelial cells, mast 
cells, endothelial cells and fibroblasts into the wound. 
The inflammation phase, which follows hemostasis, is characterized by 
spatial and temporal changing patterns of leukocyte subsets, proceeding 
from neutrophils to macrophages to lymphocytes.  Serotonin, NO, 
histamine, PGI1, PGE1, LTC4/D4 and bradykinins causes vasodilation 
and increased permeability of local vasculature. Neutrophils, the first cell 
population to arrive at the site of injury, moves from the intravascular 
space into tissues via margination and diapedesis. They not only 
scavenge the wound bed of cellular debris, bacteria and foreign bodies, 
but also secrete inflammatory products (NO, H2O2, oxygen free radicals) 
and initiate the first stages of the proliferative phase by elaboration of IL1 




Within 48 – 96 hours, circulating monocytes becomes macrophages 
upon crossing the vessel walls. In addition to phagocytosis of cell debris 
and apoptotic neutrophils, macrophages are involved in the orchestration 
of a wide range of growth factors necessary for the healing process to 
move into the proliferative phase. These growth factors attract and 
stimulate local endothelial cells, fibroblasts and keratinocytes to begin 
the repair function, matrix deposition, neovascularization and 
angiogenesis. Factors elaborated influences the chemotaxis and 
proliferation of fibroblasts and keratinocytes (PDGF, TGF-β, TNF-α,IL1, 
KGF7), angiogenesis (VEGF, FGF2, PDGF), and deposition of ECM 
(PDGF, TGF-β, TNF-α,OPN, IL1, collagenases, MMPs). The role of 
macrophages is considered critical to wound healing, as their depletion is 
shown to result in poor debridement, delayed fibroblast proliferation and 
inadequate angiogenesis(18). 
Lymphocytes are seen within wounds beginning day 5 – 7.They can be 
divided into B and T lymphocytes, based on their respective sites of 
development in the thymus and bone marrow. Apart from modulating 
immune responses, T lymphocytes are proposed to be involved in the 
process of wound healing via regulation of collagenases and ECM 
remodelling. These cells can be subdivided into 4 major subsets with 
specific functions; helper, cytotoxic, memory and regulatory T cells. Of 
these, the T helper cells (Th cells), also known as CD4+ cells, have been 






The process then transitions into the proliferative phase, lasting for up to 
2 – 4 weeks. This phase begins with the degradation of the fibrin-platelet 
provisional matrix, effected by 3 major classes of proteases: serine 
proteases, cysteine proteases, MMPs). The MMPs are endopeptidases 
(collagenase, gelatinase, stomelysin), and are responsible for degrading 
matrix proteins and activating growth factors. The functions of the 
proliferative phase can be divided into 4 major processes: fibroplasia, 
granulation, contraction, epithelialization.  
Fibroblasts from perivascular tissue migrate along fibrin networks into 
wound. They undergo hypertrophy (by increasing protein synthesis 
needed for cell division) and hyperplasia (proliferation). Fibroblasts takes 
over macrophages to become the predominant cell type at day 3 to day 5 
in clean wounds. Fibroblasts secretes hyaluronidases to digest the 
provisional extracellular matrix of hyaluron and fibronectin. Larger 
sulphated GAGs (chondroitin-4-sulphate, dermatan sulphate, heparin 
sulphate) are then secreted, along with the deposition of collagen and 
elastin in a disorganized manner. Major fibrillary collagens in the ECM 
are type I and III in the ratio of 4:1.  
The hallmark of granulation tissue formation is angiogenesis. Tissue 
hypoxia, thrombus, platelets and VEGF secreted by activated 
macrophages and fibroblasts serve as stimulus for angiogenesis. VEGF 
causes the proliferation of endothelial cells. Endothelial cells secrete 
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zinc-dependent MMPs to degrade the ECM to make way for cell 
migration, while their leading tips express Integrin αVβ3 which causes 
directional endothelial cell migration. This process eventually results in 
the formation of a dense population of blood vessels.  
Wound contraction is effected by myofibroblasts, specialized 
fibroblastswith contractile cytoplasmic microfilaments (filamentous actin) 
and distinct cellular adhesion structures (desmosomes, maculae 
adherens). They are present throughout the granulating wound, and 
contract in concert to result in a centripetal force which pulls the wound 
edges circumferentially. In response to KGF, keratinocytes re-establishes 
the epithelial layers. They undergo mobilization by losing contact 
inhibition at the wound edges, followed by migration via leapfrogging, 
guided by ‘railroad tracts’ of tenascin and fibronections. Upon completion 
of wound bridging, they regain contact inhibition and differentiate into the 
layers of the epidermis.  
 
Remodelling 
The final phase, remodelling, begin at 2 – 4 weeks after wounding, and 
may last up to 1 – 2 years. This phase aims to replace granulation tissue 
with the stronger avascular scar tissue. As the equilibrium between 
collagen synthesis and degradation is reached, no net change in the 
quantity of collagen is observed. Instead, the existing collagen fibres 
remodel from type III to type I, and undergo cross-linking to improve 
tensile strength. Collagen is degraded by MMP 1, 2, 3, 9, and deposited 
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by TIMP. Cutaneous wound healing eventually results in wound strength 
of 3% at 1 week, 30% at 3 weeks, and 80% at 3 months as compared to 
that of uninjured skin.  
 
1.1.3(b)Pathological Wound Healing in Keloid Scarring 
As scar formation is the ultimatum of the wound healing process, any 
abnormality in any of its phases may result in pathological scarring.  
 
Inflammation 
After wounding, the internal milleau is exposed to a variety of agents that 
are capable of prolonging or exaggerating this phase. These include 
microorganisms and foreign bodies, which are usually promptly 
eliminated by neutrophils and macrophages during inflammation.  
It has been found that both the severity, as well as type of immune 
response can result in HTS and keloids. Of particular mention is the roles 
of Th cells in fibrogenesis. The characteristic cytokine expression profile 
of Th cells represents the basis for describing either a predominantly Th1 
or Th2 response to a specific or unspecific stimulus (19). A Th2 response 
(with production of interleukin IL-4, IL-5, IL-10 and IL-13) has been 
strongly linked to fibrogenesis, while a predominance of Th1 cells has 
been shown to almost completely attenuate the formation of tissue 
fibrosis via production of IFN-γ and IL-12 (20, 21). 
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Nevertheless, the elaboration of these mediators are essential for 




Failure to improve fibroproliferative diseases, not only that of skin but 
also those involving internal organswith anti-inflammatory therapy 
provide the basis that inflammation is not the critical step in the 
development of the fibrotic response. Abnormalities in fibroblasts, TGF-β 
and the SMAD pathway, mast cells and the interactions between 
keratinocytes and fibroblasts have been implicated. 
Alterations in the fibroblast phenotype is seen in keloids. As compared to 
normal fibroblasts, keloid fibroblasts exhibit higher numbers of growth 
factor receptors and greater response to growth factors like PDGF, TGF-
β, IGF and IL-1, which results in upregulation of their functions. 
TGF-β1, -β2 and -β3 are the principal isoforms of TGF-β found in 
mammals. TGF-β1 and -β2 stimulates ECM deposition, while TGF-β3 
inhibits it. Over-expression of TGF-β1 and -β2 and under-expression of 
TGF-β3 have been found in keloids and keloid-derived fibroblasts. The 
SMAD pathway is the downstream signal transduction pathway for TGF-
β action(25) (Figure1.2).  
SMAD intracellular signaling proteinscan be categorized into receptor-
regulatedSMADs (R-SMADs), common-mediatorSMADs (co-SMADs), 
and inhibitory SMADs (22).The pathway begin by the binding of TGF-β  to 
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its cell surface receptor. This results in phosphorylation and activation of 
the type I receptor. The activated type I receptor then phosphorylates 
and activates the R-SMADs (SMAD 2, 3 and 4). These R-SMADS is then 
able to form complexes with the common mediator Co-SMAD SMAD 4. 
The complex of R-SMADs and Co-SMAD then translocates to the 
nucleus. The end point of the activation of this pathway is the activation 
of target genes in the nucleus, mediating their expression via the 
biological effects of TGF-β. SMAD 7 has inhibitory actions on the 
pathway via prevention of phosphorylation of R-SMADs. Hence, 
manipulation of this pathway, specifically by downregulating SMAD 2, 3 
and 4, and/ or upregulating SMAD 7 may be potential targets in the 
management of pathological scarring.  
Keratinocytes have been found to influence the activity of fibroblasts. 
With its secretion of KGF, and its interaction with fibroblasts to form the 
basement membrane via deposition of laminin and type IV collagen, 
keratinocytes have an intimate collaboration with fibroblast in the process 
of epithelialization.Co-culturing of keratinocytes with keloid-derived 
fibroblasts have been shown to result in greater neodermis thickness(23). 






Figure1.2: The SMAD signal-transduction pathway as a downstream 
mediator of TGF-β action 
 
Increased numbers of mast cells are seen in active keloids. Their 
secretion of proinflammatory mediators such as histamine, heparin and 
cytokines are responsible for the symptoms of pruritus and erythema 
commonly experienced by patients with keloids. These mediators, 
however, have also been found to promote fibroblast proliferation. 
 
Remodelling 
A delicate balance of ECM degradation by MMPs and its deposition by 
TIMPs is maintained throughout the normal remodelling process. MMP-2 
has been found to degrade collagen type III, while MMP-9 degrades 
collagen type I, resulting in the final outcome of collagen type I to type III 
of 4:1 in normal scar tissue. In keloids, high levels of MMP-2 and low 
levels of MMP-9 can resulting in the ratioto be as high as 17:1.  
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Decorin, a small proteoglycan with one dermatan sulfate sugar chain, is 
found in normal dermal ECM. It binds and neutralizes the action of TGF-
β. Lower levels than normal has been found in keloids. This suggests 
that decorin may have a role as an antifibrotic agent in keloids(24). In 
addition, delayed apoptosis of myofibroblasts and a continuing high-
turnover state similar to the proliferative phase is also proposed in the 
pathogenesis of keloids. 
 
1.1.4 Clinical Features 
Keloids not only result in bothersome physical symptoms, but is also 
associated with significant psychosocial impact.  
Typical complaints include a painful, red, pruritic and often unsightly 
‘growing’ scar, of which extends onto normal skin beyond the borders of 
the initial injury. Physical examination usually shows a thick warm lesion 
with erythematous edges encroaching onto normal skin. They often have 
site-specific shapes, namely, the typical butterfly,crab’s claw, and 
dumbbell shapes on the shoulder, anterior chest, and upper arm, 
respectively(17). In relation to its size, keloids canbe further subdivided 
into minor (focally raised) and major (>0.5cm in thickness) keloids(25). 
Scar tissue projecting beyond the original wound margins is the cardinal 
distinguishing feature of keloids from HTS. In addition, they tend to 
appear years after cutaneous insult, is persistent, does not regress 




1.1.5 Management Options for Keloid 
Keloid scarring remains difficult to improve despite a plethora of 
advocated treatment strategies as frequently observed in daily clinical 
routine (27). Various modes of treatment ranging from non-invasive 
strategies to surgical intervention have been proposed and utilized over 
the past decades. The outcome of usage of these modalities as 
monotherapy or in combination, and in  consecutive or concurrent 
fashion has been studied. Multimodality treatment is often recommended 
for optimum control of the disease. 
These modalities can be grouped into conservative, non-surgical and 
surgical therapies. Conservative approaches include silicone gel 
sheeting, silicone tapping, pressure therapy (scar massage, pressure 
garment), as well as make-up/ camouflage therapy. Non-surgical 
modalities include topical applications (silicone gel, onion extract, 
imiquimod 5% cream), and injectibles (intralesional TAC, intralesional 
cryotherapy, 5-fluorouracil, interferon, recombinant TGF β). Finally, 
surgery may be opted to either radically excise the lesion, or merely for 
mass reduction. 
 
1.1.6 Management in our Setting 
In our setting, patients who are diagnosed with keloid scarring are 
commenced on intralesionally instituted TAC, in combination with advice 
for scar massage. TAC with the concentration of 10mg/ml aregiven every 
17 
 
4 – 6 weeks. This combined therapy is both clinically potent and cost 
effective. 
 
1.1.7Intralesional Triamcinolone Acetonide (TAC) Injection 
TAC is a synthetic corticosteroid.One of the earliest uses of triamcinolone 
acetonide for the treatment of keloids was reported in 1965 - 9-year-old 
girl with keloid scarring secondary to burn injury (28).TAC is central in the 
management of keloid. It’s use as a monotherapy in fixed, escalating or 
tapering doses, or in combination with other modalities has been widely 
studied(29)(Figure 1.3). 
The TAC used in our centre is of concentration 10 mg/ml, preserved in 
benzyl alcohol, and is available in 5ml sterile glass vials(30) (Figure 1.4). 
The solution is administered using 1cc syringes with 27 gauge needles 
for a more precise control of infiltration. In general, the solution is 





Figure 1.3:Review of the evidence and current developments in 
corticosteroid intralesional injection treatments 






Interval Result  Side effect 
Park et al.  
(2013) 
Keloids Surgical excision 
+ full thickness 
skin graft + 
postoperative 
TAC 




- 78.5%: successful  
treatment 
- 21.5%: recurrence 
- Recurrence  
- Slight marginal 
elevation & redness 
Martin et al.  
(2013) 
Keloids CO2 fractional 
laser (10,600 
nm), pulsed dye 
laser (585 nm), 
TAC 
TAC 40 mg/ml 0.5 ml + 0.4 ml 
lidocaine with epinephrine 




- Minimal flatness 
- Minimal effect on size 
- Diminished pruritus 











TAC 40 mg/ml 4–5 mg/cm2 
(0.10–0.125 ml in a syringe of 
0.5 ml) 
3 monthly - Flattening 







Son et al.  
(2014) 
Keloids and  
hypertrophic  
scars 
578 nm copper 
bromide Laser + 
TAC 




- Reduced vascular 
components of scars 
- Decreased erythema 
- Improved pruritus 
- Improve telangiectasia 
8%: ≤25% improvement 
17%: 25 - 50% improvement 
33%: 51 - 75% improvement 
42%: ≥75% improvement 
- Moderate pain 
during treatment 




Emad et al.  
(2010) 
Keloids Surgical excision 
+ immediate 
postoperative 
radiotherapy vs.  
Cryotherapy + 
TAC 
TAC 10 mg/ml 
(maximum 40 mg/ session) 
Every 20 days - 66.7%: satisfied 
- 22.2%: partially satisfied 
- 11.1%: unsatisfied 
- Hypopigmentation 
(9.4%) 






et al.  
(2011) 
Keloids 5-fluorouracil  
Tattooing + TAC 
TAC 40 mg/ml  
(20 mg (0.5 ml)/ cm2 lesion) 
4 weekly for 12 
weeks 
- Reduced erythema & 
pruritus 
- Reduced surface & height 
NA 




with core fillet 
flap + TAC 
TAC 40 mg/ml (0.25 ml) Monthly - Efficacy: 87.6% 
- Immediate recurrence: 9.5% 
- Subjectively, 82.3% patients 
were highly satisfied 
- Full-flap necrosis 





Keloids TAC - Non-bearded area of face 
(mean dose 8.75 mg) 
- Bearded area, upper limb, 
earlobes, occipital, sternum 
(mean dose 20.37 mg) 
- Regimen 1: 10 mg/ml 
- Regimen 2: 40 mg/ml 
- Regimen 3: 10 then 40 
mg/ml 
- Regimen 4:10 then 40 then 
10 mg/ml 
- Regimen 5: 40 then 10 
mg/ml 
4 weekly Regimen 3 was the most 
effective, with the lowest 
recurrence rate (10%) 
Recurrence: 
- Regimen 1: 22%  
- Regimen 2: 25%  
- Regimen 3: 10%  
- Regimen 4: 24%  




Keloids and  
hypertrophic  
scars 
TAC (review) TAC 10–40 mg/ml Monthly Decreased recurrence rates, 
collagen and  
glycosyminoglycan synthesis, 












Keloids 5-fluorouracil + 
TAC 
 
TAC 0.1 ml of solution/cm 
lesion 
4 weekly - 92% average reduction in 
lesion size 
- Reduction of pruritus 
- Pain resolved 
Telangiectasias 
Gupta et al.  
(2011) 






Generally TAC 10–20 mg/ml, 
40 mg/ml for tough bulky 
lesions 





Figure 1.4:TAC in 10mg/ml preparation (Shincort by Y.S.P. 
Industries) 
 
The intralesional administration of TAC is known to decrease 
inflammation, increase vasoconstriction and  inhibit fibroblast proliferation 
in a dose-dependent fashion (31). Via the inhibition of fibroblast 
proliferation and collagenase inhibitors, collagen and glycosaminoglycan 
synthesis is reduced(32). On top of that, it also decreases the production 
of inflammatory cytokines, chemokines, and lysosomal enzymes(33).More 
recently, TAC has been found to inhibit vascular endothelial growth factor 
(VEGF)and TGF-β1 expression and to induce apoptosis in fibroblasts (34, 
35). 
When used as monotherapy, steroid injectionshave a highly variable 
response rate of 50% to 100%and a recurrence rate of 9% to 50%(32).In 
general, existing studies on the applications of intralesional triamcinolone 
acetonide for keloid scars not only resulted in a reduction in extension 
and thickness of the keloid scar, but also an improvement in clinical 
symptoms of pruritus, pain, and hyperemia(36). 
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1.1.8 Scar Massage 
The exact mechanism of massage in improving keloids remains 
unknown. Several studies suggest that scar massage can alter ECM 
remodelling and influence fibroblast apoptosis. It is proposed that the 
mechanical forces of scar massage can alter the structural and signalling 
milleau within scars via induction of changes in the expression of ECM 
proteins and proteases, on top of increasing scar pliability by disrupting 
fibrotic tissue(37).Furthermore, in vitro studies on human scar tissue 
showed that pressure can induce apoptosis and reduce TNF-α levels(38). 
Besides being cheaper, scar massage allows patients to be more 
involved in their treatment and aids in the resolution of swelling and 
induration of scars(37).However, itcan also cause irritation from friction 
and contact dermatitis from the lubricant used, in addition to be a waste 
of patient’s time if it is not an efficacious treatment(37). 
Shin et al. recommends friction massage with the application of sufficient 
pressure to blanch the scar for 10 minutes twice a day, titrated up 
ordown as tolerated(37).This therapy is not suitable in open wounds, acute 
infections and bleeding. Massage is best performed with clean hands 
and hypoallergenic emollients. 
 
1.1.9 Algorithm for Management of Keloids 
In addition to the vast degree to which keloids respond to various 
treatment modalities, numerous variables found to influence the outcome 
oftreatment makes its management even more challenging. These 
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include ethnicity, age, gender, site and size of keloids, and the methods 
used to measure response rates and patient satisfaction. In view of this 
high variability of response rates, earlier algorithms suggest less invasive 
modalities such as silicone sheeting or TAC for a duration of 3-12 
months, before opting for more invasive modalities such assurgery(25). 
In 2010, Ogawa proposed an algorithm for the management of keloids 
after extensive evidence-based review of relevant literature(39)(Figure 
1.5). The algorithm suggests to stratify patients according to size and 
number of lesions present. Small and/or single lesions can either be 
treated with excision and adjuvant therapy, or with non-surgical 
monotherapy. On the other hand, goals of treatment should first be set in 
patients with large and/or multiple lesions, or those with lesions limiting 
range of motion. These latter group of patients may either opt for mass 
reduction surgery or symptomatic management with non-surgical 
multimodality therapy. Long-term follow-up is recommended for all 
patients with keloids. 
All patients recruited for assessment in this study presented with small 
single lesions. Therefore, in accordance with the treatment algorithm for 
keloids suggested by Ogawa, patients were started on non-surgical 
monotherapy with intralesional TAC. The monotherapy was 






Figure 1.5:Treatment Algorithms for Keloids 
 
 
1.1.10Patient Observer Scar Assessment Scale (POSAS) 
The POSAS is a scoring system for subjective scar assessment which 
focuses on scar severity from both the clinician’s and patient’s point of 
view. It was first published by Draaijers et al. in 2004 (Version 1.0). A 
year later, Van Der Kar et al. published POSAS version 2.0 (POSAS 
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v2.0). Further development and refinement of the scale is still underway. 
The POSAS v2.0 is the version utilized in this study. 
The scoring system consists of 2 numerical scales – the patient (Figure 
1.6) and the observer (Figure1.7) scales v2.0(40). Although the scale was 
initially developed with a focus on burn scars, it has been applied in 
assessing various types of scars, including linear surgical scars. Its uses 
include evaluation of response to treatment, evaluation of new therapies, 
and as a tool for communication between clinicians (41). 
Each of the 2 scales consists of 6 items that are scored numerically on a 
ten-step scale. The score of 10 corresponds to the worst imaginable 
scar. Each of these items carry a minimum score of 1 and a maximum 
score of 10. The sum of scores from both of the scales make up the 
‘Total Score’ of the POSAS, with a minimum total score of 6, and the 
maximum total score of 60. In addition, the patient and the observer each 
also score their ‘Overall Opinion’ on a ten-step scale. During scoring, all 
parameters are compared to the normal skin at a comparable anatomical 




Figure 1.6:POSAS Patient Scale v2.0 
